Jonathan Spicer MD PhD
@DoctorJSpicer
Followers
4K
Following
9K
Media
244
Statuses
5K
Medical Director of the McGill Thoracic Oncology Program; Chest surgeon; Neutrophil biologist; Cancer immunologist; Aspiring farmer
Montréal, Québec
Joined May 2011
Great thread, proud of @Joshua_Reuss & many pt/colleagues in bringing to fruition this neoadjuvant immunotherapy trial for mesothelioma w cutting edge liquid biopsy data from @ValsamoA , now open access @NatureMedicine ! https://t.co/POwrWNbl1R
@curemeso @cancertrials_ie #WCLC25
Honored to present our data on neoadjuvant nivolumab and nivolumab/ipilimumab in potentially resectable diffuse pleural mesothelioma (DPM) at #WCLC25. @IASLC We evaluated perioperative nivo and nivo/ipi in epithelioid or biphasic DPM deemed resectable by multi-D assessment. 1/7
0
6
25
A new model of #TumorNecrosis Beyond outgrowing vascular supply, tumors also recruit destructive immune cells to block the blood flow👹 Tumor CXCL1 (+likely other secretome)➡️myeloid skewing➡️ Ly6C-low Neutrophil (transcriptomically similar populations observed in human
0
14
57
Surgical outcomes correlation with 5 year survival with neoadj chemo IO for lung cancer in CheckMate 816 presented by the legendary Prof. @t_mitsudomi #WCLC25 overall v good outcomes, remarkably so for pts with pneumonectomy #LCSM
2
27
63
START-new-ERA #WCLC25 investigates ablative dose of SABR in #lungcancer with chemo+immunotherapy in locally advanced NSCLC. Tolerable and quite encouraging results… 💪🏽 time to bring a 🔨 to old ideas of long course RT #radonc? #LCSM
0
31
67
@DrewMoghanaki @DoctorJSpicer @MARIANOPROVENCI @JieDengMDPhD @LeciaSequist @max_diehn @CharuAggarwalMD @n8pennell @JackWestMD @ArjanGower I don’t get the question, the HR in PD-L1 negative in all these studies is <1 and in a couple of them very similar to PD-L1 positive. Among the 16% of pts in 816 with pCR in PD-L1 negative nearly all or all are alive at 5 years (I don’t have specific breakdown)
1
2
3
@MattSmeltzer @NarjustFlorezMD @DoctorJSpicer among the lung med oncs favorite surgeons describes his path as a clinician scientist! #wclc25
1
4
15
@DrewMoghanaki @FordePatrick @DoctorJSpicer @MARIANOPROVENCI @JieDengMDPhD @LeciaSequist @max_diehn @CharuAggarwalMD @n8pennell @JackWestMD Still 17 percent of people who are PD-L1 neg achieve path CR with neoadjucant chemoIO (vs 3% with chemo) and it’s important to figure out why biologically certain patients benefit
2
2
6
Dr. @salmajabbour1 reminded folks at #ELIXR25 about the promising HORIZON-1 study for stage III NSCLC with ALK, ROS1, RET, and TBD actionable mutations. @Roche #radonc
https://t.co/Mlsd7ef7FI
2
5
23
Do we need to change the SoC Ttx for Pancoast NSCLC🫁? Cohort of cases treated: induction CTIO —>Surgery. pCR 100%, strong prognostic marker in these rare 🫁.We discuss challenges to apply this approach in daily practice. High expertise surgery needed https://t.co/OKWIuBUHgl
0
30
65
🌟 Excited for the Oncology Career Strategies session at #WCLC25! Part of the Early Career Investigator Workshop, this session will focus on navigating early → mid-career, clinician-scientist roles & diverse career pathways in oncology Sept 6 | 10:00–11:30 CEST | Barcelona
1
7
27
☑️#WCLC25 #LCSM Mini Oral Abstract🆙 🔥Nautika1: Clinical Outcomes and Pathologic Regression With Neoadjuvant Alectinib in Resectable Stage IB-IIIB ALK + NSCLC 🎯MPR 17/28 (60.7%), pCR 7/28 (25.0%) 🎙️ Dr. Jay M. Lee @OncoAlert @Larvol @IASLC
https://t.co/qYfDgCOHNE
0
10
30
Another inspiring lab meeting with our brilliant students. Very pleased that the Spicer lab can celebrate 10 years of science with continuous funding from various sources. Couldn’t have done it without my research partner @ronirayes who has been there from the beginning and all
2
8
47
Excited to share our newest paper on the essential role of neutrophils in cancer
nature.com
Signal Transduction and Targeted Therapy - Neutrophil-specific targeting of STAT3 impairs tumor progression via the expansion of cytotoxic CD8+ T cells
0
25
89
ELIXR is essentially one of the best clinically orientated lung cancer conferences out there...outstanding its now available online, thanks @DoctorJSpicer
Check out the talks from ELIXR25! Fantastic content from folks like @HenningWillers @DrJNaidoo @SalmaJabbour1 @maraantonoff Prof Wenzhao Zhong and many others! https://t.co/zRmhFNRIGC via @YouTube
1
3
8
Visual graphic research summary now out for the CheckMate 816 trial in the New England Journal of Medicine! #lcsm @LUNGevity @CancerInstIRE @cancertrials_ie
In resectable lung cancer, neoadjuvant nivolumab plus chemotherapy improved 5-year overall survival, with no lung cancer deaths reported at 5 years in patients with a pathological complete response. Full CheckMate 816 phase 3 trial results and Research Summary:
2
21
64
Check out the talks from ELIXR25! Fantastic content from folks like @HenningWillers @DrJNaidoo @SalmaJabbour1 @maraantonoff Prof Wenzhao Zhong and many others! https://t.co/zRmhFNRIGC via @YouTube
youtube.com
Early-stage Lung cancer International eXpert Retreat - #ELIXR. This conference aims to bring innovative minds together to foster education and inspire discussions aimed at practical clinical manage...
0
10
28
Last wk to apply! Come spend a yr with us in beautiful Montreal honing your expertise in UpperGI and Thoracic Surgery. Great opportunity with my amazing colleagues! @DoctorJSpicer @JonathanCools @sara_najmeh @LFerri123
mcgill.ca
McGill Advanced Thoracic and Upper Gastrointestinal Surgical Oncology Fellowship The McGill Advanced Thoracic and Upper GI Surgical Oncology Fellowship offers a world-class training experience at the
0
4
5
Durvalumab after radiotherapy in patients with unresectable stage III non-small-cell lung cancer ineligible for chemotherapy: the DUART phase II nonrandomized controlled study☆ - ESMO Open
esmoopen.com
Currently, patients with unresectable stage III non-small-cell lung cancer (NSCLC) ineligible for chemotherapy receive radiotherapy alone, with unsatisfactory results. DUART was a phase II single-arm...
2
13
36
Phase III KRYSTAL-12 Trial: Adagrasib improved outcomes over docetaxel in pts with previously treated locally advanced/metastatic KRAS G12C+ NSCLC @barlesi @TonyMok9 #TargetedTherapy 🔹PFS: 5.5 vs 3.8 mo (HR = 0.58) 🔹ORR: 32% vs 9% (OR = 4.68) https://t.co/ablXmRwphh
1
3
13
Original Article: Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer (CheckMate 816 phase 3 trial) https://t.co/Y8bQ4TcwiP Redefining Lung Cancer Therapy — A Long-Awaited Shift in Strategy https://t.co/Ql7k6tRZbY
#Oncology
0
34
84